Search research articles
Contact Us
Filters
Showing results (261-270 of 288) with videos related to
Page
of 29
Sort By:
Leukemia
|
September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
E Terpos, M A Dimopoulos, O Sezer, et al.
Blood Cancer Journal
|
June 17, 2017
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
E Kastritis, M Gavriatopoulou, M Roussou, et al.
The New England Journal of Medicine
|
February 22, 1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group
J R Berenson, A Lichtenstein, L Porter, et al.
Leukemia
|
February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M A Dimopoulos, A Palumbo, M Attal, et al.
Leukemia
|
February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos, X Leleu, A Palumbo, et al.
British Journal of Cancer
|
November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
A K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
A Bamias, U Dafni, A Karadimou, et al.
Breast Cancer Research and Treatment
|
May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study
G Fountzilas, U Dafni, M A Dimopoulos, et al.
Blood Cancer Journal
|
April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos, A K Stewart, T Masszi, et al.
Blood Cancer Journal
|
August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
J Hillengass, L A Moulopoulos, S Delorme, et al.
Page
of 29
Search research articles
Search
Showing results (261-270 of 288) with videos related to
Sort By:
Page
of 29
Leukemia
|
September 3, 2010
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group
E Terpos, M A Dimopoulos, O Sezer, et al.
Blood Cancer Journal
|
June 17, 2017
Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
E Kastritis, M Gavriatopoulou, M Roussou, et al.
The New England Journal of Medicine
|
February 22, 1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group
J R Berenson, A Lichtenstein, L Porter, et al.
Leukemia
|
February 5, 2011
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
M A Dimopoulos, A Palumbo, M Attal, et al.
Leukemia
|
February 6, 2014
Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
M A Dimopoulos, X Leleu, A Palumbo, et al.
British Journal of Cancer
|
November 6, 2008
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study
A K Koutras, K T Kalogeras, M-A Dimopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)
A Bamias, U Dafni, A Karadimou, et al.
Breast Cancer Research and Treatment
|
May 17, 2008
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study
G Fountzilas, U Dafni, M A Dimopoulos, et al.
Blood Cancer Journal
|
April 22, 2017
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment
M A Dimopoulos, A K Stewart, T Masszi, et al.
Blood Cancer Journal
|
August 26, 2017
Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
J Hillengass, L A Moulopoulos, S Delorme, et al.
Page
of 29